The high price of the drugs can result in substantial net new costs to health plans
The effect is not unique to Ozempic or other GLP-1 receptor agonists
Mehmet Oz, administrator for the Centers for Medicare & Medicaid Services, in a statement
The encouraging part is that simple, practical strategieslike balanced nutrition, strength training, improving sleep, and managing stresscan make a real difference in reducing weight rebound and keeping your metabolism supported after stopping GLP-1 medications
Key takeaways Chinas GLP-1 market is booming, driven by rising diabetes and obesity prevalence, expanded indications (e.g., MASH, CKD, Alzheimers), policy support and momentum from global leaders and innovative local players